TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01035346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of a placebo
Study: NCT00206882
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02981524
Drug: CY
Normalized name: CYT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CY is administered intravenously at 200 mg/m2
Study: NCT00984581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
Study: NCT04485689
Drug: Placebo - alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours
Study: NCT04485689
Drug: Placebo - ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
Study: NCT01300351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
Study: NCT02677844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03277261
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03277261
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an IV infusion.
Study: NCT01252290
Drug: Lovaza™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules daily for 6 months
Study: NCT02949388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
Study: NCT01123473
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01123473
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00722917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
Study: NCT00940784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, aspirin (81-100 mg qd) plus hydroxyurea
Study: NCT00875173
Drug: Placebo (for Selenium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with similar flavor, smell and colour.
Study: NCT04334213
Drug: D745, D150
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT04334213
Drug: CKD-501, D745, D150
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT04033094
Drug: Comparator Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: This was a retrospective, non-interventional study. Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
Study: NCT00286221
Drug: PCA fentanyl
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted
Study: NCT00286221
Drug: PRN fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
Study: NCT02616770
Drug: S1226 (4%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
Study: NCT02616770
Drug: S1226(8%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
Study: NCT02616770
Drug: S1226(12%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
Study: NCT02771626
Drug: CB-839
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutaminase inhibitor
Study: NCT01848470
Drug: CG400549 640mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
Study: NCT01848470
Drug: CG400549 320 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
Study: NCT01848470
Drug: CG400549 640 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
Study: NCT01848470
Drug: CG400549 960 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
Study: NCT01848470
Drug: Placebo 640mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
Study: NCT01848470
Drug: Placebo 320mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
Study: NCT01848470
Drug: placebo 960 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
Study: NCT01848470
Drug: Placebo 640mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
Study: NCT02115360
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
Study: NCT01507285
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial single dose followed by subsequent multiple s.c. (under the skin) doses
Study: NCT04145570
Drug: Tarceva®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarceva® 150 mg
Study: NCT00002816
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002816
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02179814
Drug: AMPT/ Demser
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
Study: NCT02179814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at the second, third and fourth medication intake time point
Study: NCT00002816
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03469921
Drug: administered therapeutic regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered therapeutic regimens
Study: NCT00747409
Drug: human regular insulin and NPH insulin (Actrapid, Protaphne)
Normalized name: insulin, regular, human Injectable Solution [Human Actrapid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: basal-bolus therapy with human regular and NPH insulin
Study: NCT04518163
Drug: placebo to TA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 110 ml saline by slow infusion before skin incision
Study: NCT00213096
Drug: Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00064402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID
Study: NCT03132025
Drug: Apatinib and Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer
Study: NCT03132025
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer
Study: NCT00351273
Drug: Doxycycline and Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
Study: NCT00351273
Drug: Azithromycin and Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
Study: NCT00351273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose
Study: NCT00810940
Drug: AbelaDrug200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP \< 20 mmHg, then IV 100 ml same schedule for 24 hours
Study: NCT04073160
Drug: Intravesicular Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.
Study: NCT03417661
Drug: HEXI-PREP By Clinell Wipes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile single sachet wipe containing 3ml solution.
Study: NCT01378429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00316420
Drug: Capecitabine (Xeloda)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
Study: NCT02574741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% of the subjects will be randomized to placebo (inactive study medication).
Study: NCT03417661
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline (0.9% w/v) wipe, containing 3ml of solution.
Study: NCT01723579
Drug: Estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily release of 1.5 mg
Study: NCT01987479
Drug: Non-Biologic DMARDs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
Study: NCT01987479
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered per investigator's discretion.
Study: NCT04510051
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04197817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design
Study: NCT04055038
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy
Study: NCT04335786
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
Study: NCT02903030
Drug: Maltose (placebo)
Normalized name: Maltose
DrugBank: Maltose (DB03323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltose with a trace amount of silicon dioxide
Study: NCT02903030
Drug: Visbiome Extra Strength
Normalized name: Visbiome Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
Study: NCT02080169
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl is used as analgesic drug in order to obtain the VAS \<3.
Study: NCT03323671
Drug: preemptive mefenamic acid
Normalized name: Meclofenamic Acid
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: preemptive analgesia before menstrual pain
Study: NCT03323671
Drug: mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mefenamic acid given only during menstruation
Study: NCT00431119
Drug: Azathioprine or Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04208087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be intravesically instilled.
Study: NCT03055390
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ml of saline intravenous
Study: NCT00658515
Drug: Evidence-based medical care for Acute Coronary Syndrome
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00658515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po daily
Study: NCT01805388
Drug: Experimental: Regeneration Treatment Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
Study: NCT00402493
Drug: ibuprofen, latanoprost, brimonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
Study: NCT00402493
Drug: Ibuprofen, brimonidine, latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
Study: NCT00402493
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 200mg
Study: NCT01058941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo LA and placebo oil capsules for 18 months
Study: NCT03712111
Drug: Norepinephrine 6 mcg
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
Study: NCT03712111
Drug: Norepinephrine 10 mcg
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
Study: NCT03712111
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic norepinephrine infusion will be started after subarachnoid block
Study: NCT02098889
Drug: hyoscine-N-butyl bromide(HBB)
Normalized name: n-butyl acrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
Study: NCT01123824
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: matching tablets~Route of administration: oral
Study: NCT00280566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
Study: NCT03065556
Drug: Vehicle Solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution containing no active drug
Study: NCT01238965
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01238965
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01237782
Drug: Denture soaking solution
Normalized name: ALCOHOL,DENATURED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
Study: NCT00849108
Drug: BMS747158
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~* Doses at rest were to range between 2.9 and 3.4 mCi.~* Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi.
Study: NCT00825721
Drug: C-KAD Ophthalmic Solution
Normalized name: urea c-13 Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 drops applied daily for 360 days
Study: NCT02757079
Drug: NPC-15
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
Study: NCT01631916
Drug: corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
Study: NCT03480009
Drug: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
Normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT02326441
Drug: KX2-361
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00795288
Drug: Simvastatin, 80 mg/day for 21 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group
Study: NCT00795288
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group
Study: NCT00748956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator (0nmol)) administered intranasally
Study: NCT01831817
Drug: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
Study: NCT01831817
Drug: 0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
Study: NCT02845531
Drug: Optimal Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02495454
Drug: Ga101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01524081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 100ml saline solution~2. - 500ml saline solution
Study: NCT01524081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 2x 100ml saline solution~2. - 500ml saline solution
Study: NCT02193594
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA\<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA\>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
Study: NCT00006184
Drug: Myeloma Immunoglobulin Idiotype Vaccine
Normalized name: vaccinia immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
Study: NCT00491374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
Study: NCT00006184
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction chemotherapy: 600 mg/m\^2 day 4 Transplant: 1200 mg/m\^2 intravenous x 4 days (days -6, -5, -4, -3)
Study: NCT00006184
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction chemotherapy: 10 mg/m\^2 day continuous intravenous (CIV) days 1-3
Study: NCT00006184
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transplant: 5 mg/m\^2 intravenous on days +1, +3, +6, +11
Study: NCT00094432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, Once daily, 8 weeks.